Anti-obesity drugs currently used and new compounds in clinical development

Figure 1 Structures of orlistat and cetilistat.

Figure 2 Patients with at least 5% and at least 10% weight loss in the CONQUER study. From[59], with permission from Elsevier.

Figure 3 Proportion of participants who lost at least 5%, 10% and 15% of baseline weight at week 56. ^bP < 0.0001 vs placebo. From[24], with permission from Elsevier.

Figure 4 Action of the orexigenic and anorexigenic hormones in the fasting and feeding states. AgRP: Agouti-related protein; GLP-1: Glucagon-like peptide-1; NPY: Neuropeptide Y; PYY: Peptide tyrosine-tyrosine; POMC: Pro-opiomelanocortin.

Figure 5 Short-term and long-term pharmacological treatment of obesity. ¹Under investigation (clinical trials); ²Anti-obesity effects being investigated. 5-HT: 5-hidroxytryptamine; CB1R: Cannabinoid-1 receptors; DA: dopamine; FDA: United States Food and Drug Administration; GLP-1: Glucagon-like peptide 1; NE: Norepinephrine; OXM: Oxyntomodulin; PYY: Peptide tyrosine-tyrosine; POMC: Pro-opiomelanocortin; T2DM: Type 2 diabetes mellitus.

Figure 6 Algorithm for assessment and treatment of overweight and obese patients. BMI: Body mass index; F: Female; Hx: History; M: Male; T2DM: Type 2 diabetes mellitus.